Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 35 for your search:
Drug:  veliparib
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00616, CALGB-A071102, A071102, U10CA031946, U10CA180821, NCT02152982

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M14-011, 2013-002377-21, NCT02032277

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-089, 2013-005020-42, NCT02106546

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-914, 2014-000345-70, NCT02163694

5.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02590, CDR0000700033, 11-02-068, 8853, N01CM62204, P30CA013330, AECM-11-02-068, NCT01351909

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-00082, 12-C-0213, CDR0000717423, P12978, PBTC-033, U01CA081457, NCT01514201

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Veli-BRCA, NCT01472783

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2009-608, NCT01489865

9.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01985, U10CA021115, ECOG-E2511, CDR0000736704, E2511, U10CA180820, NCT01642251

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VeTo, NCT01690598

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02009, A091101, U10CA031946, N01CM62201, U10CA180821, NCT01711541

12.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 097517, NCT01042379

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-895, 2011-002913-12, NCT01506609

14.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01149, CDR0000730114, UCCRC-IL057, 12-0109, 9012, N01CM00038, U01CA062491, P30CA014599, N01CM00039, N01CM00071, U01CA070095, IL057, NCT01576172

15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00864, CDR0000732189, MSKCC-12-045, 12-045, 8993, N01CM00032, N01CM00071, P30CA008748, U01CA069856, NCT01585805

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01130, 12-021, CDR0000737062, IRB # 12-021, 9026, U01CA070095, N01CM00039, UM1CA186691, P30CA008748, NCT01638546

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12G.376, 2012-47, NCT01818063

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130105, 13-C-0105, NCT01827384

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M14-359, 2014-002565-30, NCT02264990

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M14-217, 2014-002866-65, NCT02305758

21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03730, CDR0000656038, GOG-9923, U10CA027469, U10CA180868, NCT00989651

22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01473, OSU-09100, CDR0000656393, 8472, N01CM62207, P30CA016058, N01CM00070, NCT01017640

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03161, AECM-000248, 10-01206, 8475, N01CM62204, P30CA013330, 00-0248, NCT01145430

24.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02552, CDR0000688990, OSU 10080, 8609, U01CA076576, P30CA016058, NCT01251874

25.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02913, NA_00043143, J1097, CDR0000691881, NA_00043143, J1097, 8813, U01CA132123, P30CA006973, UM1CA186691, U01CA070095, UM1CA186644, NCT01264432
1   
New Search